

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Monday, January 28, 2008

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L12	L11 (@ay<2004)	481
<input type="checkbox"/>	L11	L8 L10	1161
<input type="checkbox"/>	L10	(organ or host or transplant\$7 or reject\$5 or graft or versus)	1374818
<input type="checkbox"/>	L9	L8	1959
<input type="checkbox"/>	L8	histone with deacetylase with (inhib\$9 or decreas\$4 or antagon\$8 or lower\$4 or bliock\$5)	1959
<input type="checkbox"/>	L7	L5 (lbh)	0
<input type="checkbox"/>	L6	L5 (organ or host or transplant\$7 or reject\$5 or graft or versus)	2
<input type="checkbox"/>	L5	20050085509.pn.	2
<input type="checkbox"/>	L4	L2 (@ay < 2005)	55
<input type="checkbox"/>	L3	L2 (@ay < 2004)	0
<input type="checkbox"/>	L2	L1 ((transplant or transplantation or rejection or reject or rejecting or graft) or (histone deacetylase))	89
<input type="checkbox"/>	L1	panobinostat or lbh589 or lbh adj 589	89

END OF SEARCH HISTORY

d L11 ibib iabs kwic hitstr 1-7

L11. ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:10367 CAPLUS <<LOGINID::20080128>>
DOCUMENT NUMBER: 148:93277
TITLE: Histone deacetylase inhibitors for treating
degenerative diseases of the eye
INVENTOR(S): Hellberg, Peggy E.
PATENT ASSIGNEE(S): Alcon, Inc., Switz.
SOURCE: U.S. Pat. Appl. Publ., 8pp., Cont.-in-part of U.S.
Ser. No. 694,309.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2008004311	A1	20080103	US 2007-836309	20070809
US 2004092431	A1	20040513	US 2003-694309	20031027 <--
CA 2504226	A1	20040527	CA 2003-2504226	20031027 <--
AU 2003286686	A1	20040603	AU 2003-286686	20031027 <--
EP 1562592	A2	20050817	EP 2003-777895	20031027 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016163	A	20050927	BR 2003-16163	20031027 <--
JP 2006508120	T	20060309	JP 2004-551572	20031027 <--
US 2007088045	A1	20070419	US 2005-531747	20050418
MX 2005PA04738	A	20050803	MX 2005-PA4738	20050503
IN 2007DN07459	A	20071109	IN 2007-DN7459	20070927
PRIORITY APPLN. INFO.:			US 2002-425576P	P 20021112
			US 2003-694309	A2 20031027
			WO 2003-US33873	W 20031027
			IN 2005-DN2543	A3 20050613

ABSTRACT:

The invention discloses compns. and methods for treating degenerative conditions and diseases of the eye with histone deacetylase inhibitors.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2008004311	A1	20080103	US 2007-836309	20070809
US 2004092431	A1	20040513	US 2003-694309	20031027 <--
CA 2504226	A1	20040527	CA 2003-2504226	20031027 <--
AU 2003286686	A1	20040603	AU 2003-286686	20031027 <--
EP 1562592	A2	20050817	EP 2003-777895	20031027 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016163	A	20050927	BR 2003-16163	20031027 <--
JP 2006508120	T	20060309	JP 2004-551572	20031027 <--
US 2007088045	A1	20070419	US 2005-531747	20050418
MX 2005PA04738	A	20050803	MX 2005-PA4738	20050503
IN 2007DN07459	A	20071109	IN 2007-DN7459	20070927

IT Organ preservation

Transplant and Transplantation

(retinal transplant preservation; histone deacetylase inhibitors for treatment of degenerative eye diseases)

IT 60-01-5, Tributyrin 4346-18-3, Phenyl butyrate 112522-64-2, CI-994
122110-53-6, AN-9 149647-78-9, SAHA 287383-59-9, Scriptaid
404950-80-7, LBH-589 414864-00-9, PXD-101

591207-53-3, LAQ-824 676599-90-9 847460-34-8, CRA026440

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(histone deacetylase inhibitors for treatment of degenerative eye
diseases)

IT 404950-80-7, LBH-589


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(histone deacetylase inhibitors for treatment of degenerative eye
diseases)

RN 404950-80-7 CAPLUS

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-
yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L11 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:99590 USPATFULL <<LOGINID::20080128>>

TITLE: Piperidin-2-one derivative compounds and drugs
containing these compounds as the active ingredient

INVENTOR(S): Takahashi, Kanji, Mishima-gun, JAPAN
Yamamoto, Shingo, Mishima-gun, JAPAN
Naka, Masao, Mishima-gun, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005085509	A1	20050421	
APPLICATION INFO.:	US 2003-495465	A1	20021121	(10) <--
	WO 2002-JP12174		20021121	<--

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-357348	20011122
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	5997	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
ABSTRACT:		

A piperidin-2-one derivative compound represented by formula (I): ##STR1##
wherein all symbols are described in the specification, or a non-toxic salt

thereof. The compound represented by formula (I) inhibits activation of p38MAP kinase, and is useful for prevention and/or treatment of various inflammatory diseases, rheumatoid arthritis, osteoarthritis, arthritis, osteoporosis, autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, ***graft*** versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, atrial myxoma, psoriasis, dermatitis, gout, adult respiratory distress syndrome (ARDS), arteriosclerosis, post-percutaneous transluminal coronary angioplasty (PTCA) restenosis or pancreatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

20021121

AB . . . autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, . . .

SUMM . . . autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, . . .

DETD . . . autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, . . .

CLM What is claimed is:
. . . autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, . . .


IT 220991-20-8P 404950-80-7P 404951-52-6P
404951-53-7P
(cyclooxygenase-2 inhibitor-histone deacetylase inhibitor combination for treatment of premalignant colon lesions, colon cancer, and other malignancies)

IT 404950-80-7P 404951-52-6P 404951-53-7P
(cyclooxygenase-2 inhibitor-histone deacetylase inhibitor combination for treatment of premalignant colon lesions, colon cancer, and other malignancies)

RN 404950-80-7 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 404951-52-6 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 404951-53-7 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L11 ANSWER 3 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:88570 USPATFULL <<LOGINID::20080128>>

TITLE: Rapid method for screening compounds for in vivo activity

INVENTOR(S): Lassota, Piotr, Succasunna, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004067540	A1	20040408	
APPLICATION INFO.:	US 2003-250739	A1	20030707	(10) <--
	WO 2002-EP106		20020108	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	1 Drawing Page(s)			
LINE COUNT:	577			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
ABSTRACT:				

The present invention provides a rapid method for screening potentially pharmaceutically useful compounds for activity in vivo. The method has the steps of growing a target cell into which a reporter gene was introduced in a biocompatible, semipermeable encapsulation device; implanting the semi-permeable encapsulation device into a subject; administering a potentially pharmaceutically active compound to said subject; removing said encapsulation device from said subject after in vivo exposure to the potentially pharmaceutically active compound and evaluating said target cell for reaction to said potentially pharmaceutically active compound by measuring the expression of said reporter gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

20020108

SUMM . . . laboratory animal; (2) orthotopic model where live tumor cells are surgically implanted or tumor cell suspensions are injected into the organ of tumor origin (i.e. prostate tumor cells into the prostate, lung tumor cells into the lungs or the subrenal tumor. . .


IT 404950-80-7P 404951-52-6P
(rapid method for screening compds. for in vivo activity)

IT 404950-80-7P 404951-52-6P
(rapid method for screening compds. for in vivo activity)

RN 404950-80-7 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 404951-52-6 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-

yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L11 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:31925 USPATFULL <<LOGINID::20080128>>

TITLE: Deacetylase inhibitors

INVENTOR(S): Remiszewski, Stacy William, Washington Township, NJ, UNITED STATES

Bair, Walter William, Mountain Lakes, NJ, UNITED STATES

Versace, Richard W., Wanaque, NJ, UNITED STATES

Perez, Lawrence Blas, Hackettstown, NJ, UNITED STATES

Green, Michael Alan, Easton, PA, UNITED STATES

Sambucetti, Lidia C., Pacifica, CA, UNITED STATES

Sharma, Sushil, West Orange, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004024067	A1	20040205
	US 6833384	B2	20041221
APPLICATION INFO.:	US 2002-299518	A1	20021116 (10) <--
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-944275, filed on 31 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307490P	20010724 (60)
	US 2001-292232P	20010518 (60)
	US 2000-229943P	20000901 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2083	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
ABSTRACT:		

The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM [0163] Where a tumor, a tumor disease, a carcinoma or a cancer are

mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or.


IT	404948-38-5P	404948-39-6P	404948-40-9P	404948-41-0P	404948-42-1P
	404948-43-2P	404948-44-3P	404948-45-4P	404948-46-5P	404948-47-6P
	404948-48-7P	404948-49-8P	404948-50-1P	404948-51-2P	404948-52-3P
	404948-54-5P	404948-55-6P	404948-56-7P	404948-57-8P	404948-58-9P
	404948-59-0P	404948-61-4P	404948-62-5P	404948-63-6P	404948-64-7P
	404948-65-8P	404948-66-9P	404948-67-0P	404948-68-1P	404948-69-2P
	404948-70-5P	404948-71-6P	404948-72-7P	404948-73-8P	404948-74-9P
	404948-75-0P	404948-76-1P	404948-77-2P	404948-78-3P	404948-79-4P
	404948-80-7P	404948-81-8P	404948-82-9P	404948-84-1P	404948-86-3P
	404948-88-5P	404948-90-9P	404948-92-1P	404948-94-3P	404948-96-5P
	404948-98-7P	404949-00-4P	404949-02-6P	404949-04-8P	404949-06-0P
	404949-08-2P	404949-10-6P	404949-11-7P	404949-12-8P	404949-13-9P
	404949-14-0P	404949-15-1P	404949-16-2P	404949-17-3P	404949-18-4P
	404949-19-5P	404949-20-8P	404949-21-9P	404949-22-0P	404949-23-1P
	404949-24-2P	404949-25-3P	404949-26-4P	404949-27-5P	404949-28-6P
	404949-29-7P	404949-30-0P	404949-32-2P	404949-33-3P	404949-34-4P
	404949-35-5P	404949-36-6P	404949-37-7P	404949-38-8P	404949-39-9P
	404949-40-2P	404949-41-3P	404949-42-4P	404949-43-5P	404949-44-6P
	404949-45-7P	404949-46-8P	404949-47-9P	404949-48-0P	404949-49-1P
	404949-50-4P	404949-51-5P	404949-52-6P	404949-53-7P	404949-54-8P
	404949-55-9P	404949-58-2P	404949-61-7P	404949-64-0P	404949-66-2P
	404949-68-4P	404949-70-8P	404949-72-0P	404949-74-2P	404949-76-4P
	404949-79-7P	404949-81-1P	404949-83-3P	404949-85-5P	404949-86-6P
	404949-88-8P	404949-90-2P	404949-92-4P	404949-94-6P	404949-95-7P
	404949-97-9P	404949-99-1P	404950-01-2P	404950-03-4P	404950-04-5P
	404950-05-6P	404950-06-7P	404950-07-8P	404950-08-9P	404950-09-0P
	404950-10-3P	404950-11-4P	404950-12-5P	404950-13-6P	404950-14-7P
	404950-15-8P	404950-16-9P	404950-17-0P	404950-18-1P	404950-19-2P
	404950-20-5P	404950-21-6P	404950-22-7P	404950-23-8P	404950-24-9P
	404950-25-0P	404950-26-1P	404950-27-2P	404950-28-3P	404950-29-4P
	404950-30-7P	404950-31-8P	404950-32-9P	404950-33-0P	404950-34-1P
	404950-35-2P	404950-36-3P	404950-37-4P	404950-38-5P	404950-39-6P
	404950-40-9P	404950-41-0P	404950-42-1P	404950-43-2P	404950-44-3P
	404950-45-4P	404950-46-5P	404950-47-6P	404950-48-7P	404950-49-8P
	404950-50-1P	404950-51-2P	404950-52-3P	404950-53-4P	404950-54-5P
	404950-55-6P	404950-56-7P	404950-57-8P	404950-58-9P	404950-59-0P
	404950-60-3P	404950-61-4P	404950-62-5P	404950-63-6P	404950-64-7P
	404950-65-8P	404950-67-0P	404950-68-1P	404950-69-2P	404950-70-5P
	404950-71-6P	404950-72-7P	404950-73-8P	404950-74-9P	404950-75-0P
	404950-76-1P	404950-77-2P	404950-78-3P	404950-79-4P	
	<u>404950-80-7P</u>	404950-81-8P	404950-82-9P	404950-83-0P	
	404950-85-2P	404950-86-3P	404950-87-4P	404950-88-5P	404950-89-6P
	404950-90-9P	404950-91-0P	404950-92-1P	404950-93-2P	404950-94-3P
	404950-95-4P	404950-96-5P	404950-97-6P	404950-98-7P	404950-99-8P
	404951-01-5P	404951-02-6P	404951-04-8P	404951-05-9P	404951-06-0P
	404951-07-1P	404951-08-2P	404951-09-3P	404951-10-6P	404951-11-7P
	404951-12-8P	404951-13-9P	404951-14-0P	404951-16-2P	404951-17-3P
	(preparation of hydroxamic acids as deacetylase inhibitors)				
IT	404951-18-4P	404951-20-8P	404951-21-9P	404951-22-0P	404951-23-1P
	404951-25-3P	404951-27-5P	404951-29-7P	404951-31-1P	404951-32-2P
	404951-33-3P	404951-34-4P	404951-35-5P	404951-36-6P	404951-37-7P
	404951-38-8P	404951-39-9P	404951-40-2P	404951-41-3P	404951-42-4P
	404951-43-5P	404951-44-6P	404951-45-7P	404951-46-8P	404951-47-9P
	404951-48-0P	404951-49-1P	404951-50-4P	404951-51-5P	
	<u>404951-52-6P</u>	404951-54-8P	404953-24-8P		
	(preparation of hydroxamic acids as deacetylase inhibitors)				
IT	<u>404950-80-7P</u>	<u>404951-52-6P</u>			

(preparation of hydroxamic acids as deacetylase inhibitors)

RN 404950-80-7 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 404951-52-6 USPATFULL

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L11 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:24219 USPATFULL <<LOGINID::20080128>>

TITLE: Deacetylase inhibitors

INVENTOR(S): Remiszewski, Stacy W., Washington Township, NJ, UNITED STATES.

Bair, Kenneth W., Mountain Lakes, NJ, UNITED STATES

Versace, Richard W., Wanaque, NJ, UNITED STATES

Perez, Lawrence B., Hackettstown, NJ, UNITED STATES

Green, Michael A., Easton, PA, UNITED STATES

Sambucetti, Lidia C., Pacifica, CA, UNITED STATES

Sharma, Sushil, West Orange, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003018062	A1	20030123	
	US 6552065	B2	20030422	
APPLICATION INFO.:	US 2001-944275	A1	20010831	(9) <--

NUMBER	DATE

PRIORITY INFORMATION: US 2001-307490P 20010724 (60)
 US 2001-292232P 20010518 (60)
 US 2000-229943P 20000901 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND
 TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ,
 079011027

NUMBER OF CLAIMS: 38
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2073
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ABSTRACT:

The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM [0162] Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or.

IT	404948-38-5P	404948-39-6P	404948-40-9P	404948-41-0P	404948-42-1P
	404948-43-2P	404948-44-3P	404948-45-4P	404948-46-5P	404948-47-6P
	404948-48-7P	404948-49-8P	404948-50-1P	404948-51-2P	404948-52-3P
	404948-54-5P	404948-55-6P	404948-56-7P	404948-57-8P	404948-58-9P
	404948-59-0P	404948-61-4P	404948-62-5P	404948-63-6P	404948-64-7P
	404948-65-8P	404948-66-9P	404948-67-0P	404948-68-1P	404948-69-2P
	404948-70-5P	404948-71-6P	404948-72-7P	404948-73-8P	404948-74-9P
	404948-75-0P	404948-76-1P	404948-77-2P	404948-78-3P	404948-79-4P
	404948-80-7P	404948-81-8P	404948-82-9P	404948-84-1P	404948-86-3P
	404948-88-5P	404948-90-9P	404948-92-1P	404948-94-3P	404948-96-5P
	404948-98-7P	404949-00-4P	404949-02-6P	404949-04-8P	404949-06-0P
	404949-08-2P	404949-10-6P	404949-11-7P	404949-12-8P	404949-13-9P
	404949-14-0P	404949-15-1P	404949-16-2P	404949-17-3P	404949-18-4P
	404949-19-5P	404949-20-8P	404949-21-9P	404949-22-0P	404949-23-1P
	404949-24-2P	404949-25-3P	404949-26-4P	404949-27-5P	404949-28-6P
	404949-29-7P	404949-30-0P	404949-32-2P	404949-33-3P	404949-34-4P
	404949-35-5P	404949-36-6P	404949-37-7P	404949-38-8P	404949-39-9P
	404949-40-2P	404949-41-3P	404949-42-4P	404949-43-5P	404949-44-6P
	404949-45-7P	404949-46-8P	404949-47-9P	404949-48-0P	404949-49-1P
	404949-50-4P	404949-51-5P	404949-52-6P	404949-53-7P	404949-54-8P
	404949-55-9P	404949-58-2P	404949-61-7P	404949-64-0P	404949-66-2P
	404949-68-4P	404949-70-8P	404949-72-0P	404949-74-2P	404949-76-4P
	404949-79-7P	404949-81-1P	404949-83-3P	404949-85-5P	404949-86-6P
	404949-88-8P	404949-90-2P	404949-92-4P	404949-94-6P	404949-95-7P
	404949-97-9P	404949-99-1P	404950-01-2P	404950-03-4P	404950-04-5P
	404950-05-6P	404950-06-7P	404950-07-8P	404950-08-9P	404950-09-0P
	404950-10-3P	404950-11-4P	404950-12-5P	404950-13-6P	404950-14-7P
	404950-15-8P	404950-16-9P	404950-17-0P	404950-18-1P	404950-19-2P
	404950-20-5P	404950-21-6P	404950-22-7P	404950-23-8P	404950-24-9P
	404950-25-0P	404950-26-1P	404950-27-2P	404950-28-3P	404950-29-4P
	404950-30-7P	404950-31-8P	404950-32-9P	404950-33-0P	404950-34-1P
	404950-35-2P	404950-36-3P	404950-37-4P	404950-38-5P	404950-39-6P
	404950-40-9P	404950-41-0P	404950-42-1P	404950-43-2P	404950-44-3P
	404950-45-4P	404950-46-5P	404950-47-6P	404950-48-7P	404950-49-8P
	404950-50-1P	404950-51-2P	404950-52-3P	404950-53-4P	404950-54-5P
	404950-55-6P	404950-56-7P	404950-57-8P	404950-58-9P	404950-59-0P
	404950-60-3P	404950-61-4P	404950-62-5P	404950-63-6P	404950-64-7P


	404950-65-8P	404950-67-0P	404950-68-1P	404950-69-2P	404950-70-5P
	404950-71-6P	404950-72-7P	404950-73-8P	404950-74-9P	404950-75-0P
	404950-76-1P	404950-77-2P	404950-78-3P	404950-79-4P	
	<u>404950-80-7P</u>	404950-81-8P	404950-82-9P	404950-83-0P	
	404950-85-2P	404950-86-3P	404950-87-4P	404950-88-5P	404950-89-6P
	404950-90-9P	404950-91-0P	404950-92-1P	404950-93-2P	404950-94-3P
	404950-95-4P	404950-96-5P	404950-97-6P	404950-98-7P	404950-99-8P
	404951-01-5P	404951-02-6P	404951-04-8P	404951-05-9P	404951-06-0P
	404951-07-1P	404951-08-2P	404951-09-3P	404951-10-6P	404951-11-7P
	404951-12-8P	404951-13-9P	404951-14-0P	404951-16-2P	404951-17-3P
	(preparation of hydroxamic acids as deacetylase inhibitors)				
IT	404951-18-4P	404951-20-8P	404951-21-9P	404951-22-0P	404951-23-1P
	404951-25-3P	404951-27-5P	404951-29-7P	404951-31-1P	404951-32-2P
	404951-33-3P	404951-34-4P	404951-35-5P	404951-36-6P	404951-37-7P
	404951-38-8P	404951-39-9P	404951-40-2P	404951-41-3P	404951-42-4P
	404951-43-5P	404951-44-6P	404951-45-7P	404951-46-8P	404951-47-9P
	404951-48-0P	404951-49-1P	404951-50-4P	404951-51-5P	
	<u>404951-52-6P</u>	404951-54-8P	404953-24-8P		
	(preparation of hydroxamic acids as deacetylase inhibitors)				
IT	<u>404950-80-7P 404951-52-6P</u>				
	(preparation of hydroxamic acids as deacetylase inhibitors)				
RN	404950-80-7 USPATFULL				
CN	2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)				

Double bond geometry as shown.



RN 404951-52-6 USPATFULL
 CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L11 ANSWER 6 OF 7 USPAT2 on STN

ACCESSION NUMBER: 2004:31925 USPAT2 <<LOGINID::20080128>>
TITLE: Deacetylase inhibitors
INVENTOR(S): Remiszewski, Stacy William, Washington Township, NJ,
United States
Bair, Kenneth Walter, Mountain Lakes, NJ, United States
Versace, Richard William, Wanaque, NJ, United States
Perez, Lawrence Blas, Hackettstown, NJ, United States
Green, Michael Alan, Easton, PA, United States
Sambucetti, Lidia Cristina, Pacifica, CA, United States
Sharma, Sushil, West Orange, NJ, United States
PATENT ASSIGNEE(S): Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6833384	B2	20041221
APPLICATION INFO.:	US 2002-299518		20021119 (10) <--
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-944275, filed on 31 Aug 2001, now patented, Pat. No. US 6552065		

	NUMBER	DATE		
PRIORITY INFORMATION:	US 2001-307490P	20010724 (60)		
	US 2001-292232P	20010518 (60)		
	US 2000-229943P	20000901 (60)		
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Lambkin, Deborah C.			
LEGAL REPRESENTATIVE:	McNally, Lydia T., Dohmann, George R.			
NUMBER OF CLAIMS:	8			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)			
LINE COUNT:	1318			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
ABSTRACT:				

The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or.

IT	404948-38-5P	404948-39-6P	404948-40-9P	404948-41-0P	404948-42-1P
	404948-43-2P	404948-44-3P	404948-45-4P	404948-46-5P	404948-47-6P
	404948-48-7P	404948-49-8P	404948-50-1P	404948-51-2P	404948-52-3P
	404948-54-5P	404948-55-6P	404948-56-7P	404948-57-8P	404948-58-9P
	404948-59-0P	404948-61-4P	404948-62-5P	404948-63-6P	404948-64-7P
	404948-65-8P	404948-66-9P	404948-67-0P	404948-68-1P	404948-69-2P
	404948-70-5P	404948-71-6P	404948-72-7P	404948-73-8P	404948-74-9P
	404948-75-0P	404948-76-1P	404948-77-2P	404948-78-3P	404948-79-4P
	404948-80-7P	404948-81-8P	404948-82-9P	404948-84-1P	404948-86-3P
	404948-88-5P	404948-90-9P	404948-92-1P	404948-94-3P	404948-96-5P
	404948-98-7P	404949-00-4P	404949-02-6P	404949-04-8P	404949-06-0P
	404949-08-2P	404949-10-6P	404949-11-7P	404949-12-8P	404949-13-9P
	404949-14-0P	404949-15-1P	404949-16-2P	404949-17-3P	404949-18-4P
	404949-19-5P	404949-20-8P	404949-21-9P	404949-22-0P	404949-23-1P
	404949-24-2P	404949-25-3P	404949-26-4P	404949-27-5P	404949-28-6P

404949-29-7P	404949-30-0P	404949-32-2P	404949-33-3P	404949-34-4P
404949-35-5P	404949-36-6P	404949-37-7P	404949-38-8P	404949-39-9P
404949-40-2P	404949-41-3P	404949-42-4P	404949-43-5P	404949-44-6P
404949-45-7P	404949-46-8P	404949-47-9P	404949-48-0P	404949-49-1P
404949-50-4P	404949-51-5P	404949-52-6P	404949-53-7P	404949-54-8P
404949-55-9P	404949-58-2P	404949-61-7P	404949-64-0P	404949-66-2P
404949-68-4P	404949-70-8P	404949-72-0P	404949-74-2P	404949-76-4P
404949-79-7P	404949-81-1P	404949-83-3P	404949-85-5P	404949-86-6P
404949-88-8P	404949-90-2P	404949-92-4P	404949-94-6P	404949-95-7P
404949-97-9P	404949-99-1P	404950-01-2P	404950-03-4P	404950-04-5P
404950-05-6P	404950-06-7P	404950-07-8P	404950-08-9P	404950-09-0P
404950-10-3P	404950-11-4P	404950-12-5P	404950-13-6P	404950-14-7P
404950-15-8P	404950-16-9P	404950-17-0P	404950-18-1P	404950-19-2P
404950-20-5P	404950-21-6P	404950-22-7P	404950-23-8P	404950-24-9P
404950-25-0P	404950-26-1P	404950-27-2P	404950-28-3P	404950-29-4P
404950-30-7P	404950-31-8P	404950-32-9P	404950-33-0P	404950-34-1P
404950-35-2P	404950-36-3P	404950-37-4P	404950-38-5P	404950-39-6P
404950-40-9P	404950-41-0P	404950-42-1P	404950-43-2P	404950-44-3P
404950-45-4P	404950-46-5P	404950-47-6P	404950-48-7P	404950-49-8P
404950-50-1P	404950-51-2P	404950-52-3P	404950-53-4P	404950-54-5P
404950-55-6P	404950-56-7P	404950-57-8P	404950-58-9P	404950-59-0P
404950-60-3P	404950-61-4P	404950-62-5P	404950-63-6P	404950-64-7P
404950-65-8P	404950-67-0P	404950-68-1P	404950-69-2P	404950-70-5P
404950-71-6P	404950-72-7P	404950-73-8P	404950-74-9P	404950-75-0P
404950-76-1P	404950-77-2P	404950-78-3P	404950-79-4P	
<u>404950-80-7P</u>	404950-81-8P	404950-82-9P	404950-83-0P	
404950-85-2P	404950-86-3P	404950-87-4P	404950-88-5P	404950-89-6P
404950-90-9P	404950-91-0P	404950-92-1P	404950-93-2P	404950-94-3P
404950-95-4P	404950-96-5P	404950-97-6P	404950-98-7P	404950-99-8P
404951-01-5P	404951-02-6P	404951-04-8P	404951-05-9P	404951-06-0P
404951-07-1P	404951-08-2P	404951-09-3P	404951-10-6P	404951-11-7P
404951-12-8P	404951-13-9P	404951-14-0P	404951-16-2P	404951-17-3P
(preparation of hydroxamic acids as deacetylase inhibitors)				
IT 404951-18-4P	404951-20-8P	404951-21-9P	404951-22-0P	404951-23-1P
404951-25-3P	404951-27-5P	404951-29-7P	404951-31-1P	404951-32-2P
404951-33-3P	404951-34-4P	404951-35-5P	404951-36-6P	404951-37-7P
404951-38-8P	404951-39-9P	404951-40-2P	404951-41-3P	404951-42-4P
404951-43-5P	404951-44-6P	404951-45-7P	404951-46-8P	404951-47-9P
404951-48-0P	404951-49-1P	404951-50-4P	404951-51-5P	
<u>404951-52-6P</u>	404951-54-8P	404953-24-8P		

(preparation of hydroxamic acids as deacetylase inhibitors)


IT 404950-80-7P 404951-52-6P

(preparation of hydroxamic acids as deacetylase inhibitors)

RN 404950-80-7 USPAT2


CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 404951-52-6 USPAT2
CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L11 ANSWER 7 OF 7 USPAT2 on STN

ACCESSION NUMBER: 2003:24219 USPAT2 <<LOGINID::20080128>>

TITLE: Deacetylase inhibitors

INVENTOR(S): Remiszewski, Stacy William, Washington Township, NJ, United States
Bair, Kenneth Walter, Mountain Lakes, NJ, United States
Versace, Richard William, Wanaque, NJ, United States
Perez, Lawrence Blas, Hackettstown, NJ, United States
Green, Michael Alan, Easton, PA, United States
Sambucetti, Lidia Cristina, Pacifica, CA, United States
Sharma, Sushil, West Orange, NJ, United States

PATENT ASSIGNEE(S): Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6552065	B2	20030422	
APPLICATION INFO.:	US 2001-944275		20010831	(9) <--

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307490P	20010724 (60)
	US 2001-292232P	20010518 (60)
	US 2000-229943P	20000901 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: McKane, Joseph K.

ASSISTANT EXAMINER: Wright, Sonya

LEGAL REPRESENTATIVE: Dohmann, George R.

NUMBER OF CLAIMS: 27

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1525

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ABSTRACT:

The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or.

IT	404948-38-5P	404948-39-6P	404948-40-9P	404948-41-0P	404948-42-1P
	404948-43-2P	404948-44-3P	404948-45-4P	404948-46-5P	404948-47-6P
	404948-48-7P	404948-49-8P	404948-50-1P	404948-51-2P	404948-52-3P
	404948-54-5P	404948-55-6P	404948-56-7P	404948-57-8P	404948-58-9P
	404948-59-0P	404948-61-4P	404948-62-5P	404948-63-6P	404948-64-7P
	404948-65-8P	404948-66-9P	404948-67-0P	404948-68-1P	404948-69-2P
	404948-70-5P	404948-71-6P	404948-72-7P	404948-73-8P	404948-74-9P
	404948-75-0P	404948-76-1P	404948-77-2P	404948-78-3P	404948-79-4P
	404948-80-7P	404948-81-8P	404948-82-9P	404948-84-1P	404948-86-3P
	404948-88-5P	404948-90-9P	404948-92-1P	404948-94-3P	404948-96-5P
	404948-98-7P	404949-00-4P	404949-02-6P	404949-04-8P	404949-06-0P
	404949-08-2P	404949-10-6P	404949-11-7P	404949-12-8P	404949-13-9P
	404949-14-0P	404949-15-1P	404949-16-2P	404949-17-3P	404949-18-4P
	404949-19-5P	404949-20-8P	404949-21-9P	404949-22-0P	404949-23-1P
	404949-24-2P	404949-25-3P	404949-26-4P	404949-27-5P	404949-28-6P
	404949-29-7P	404949-30-0P	404949-32-2P	404949-33-3P	404949-34-4P
	404949-35-5P	404949-36-6P	404949-37-7P	404949-38-8P	404949-39-9P
	404949-40-2P	404949-41-3P	404949-42-4P	404949-43-5P	404949-44-6P
	404949-45-7P	404949-46-8P	404949-47-9P	404949-48-0P	404949-49-1P
	404949-50-4P	404949-51-5P	404949-52-6P	404949-53-7P	404949-54-8P
	404949-55-9P	404949-58-2P	404949-61-7P	404949-64-0P	404949-66-2P
	404949-68-4P	404949-70-8P	404949-72-0P	404949-74-2P	404949-76-4P
	404949-79-7P	404949-81-1P	404949-83-3P	404949-85-5P	404949-86-6P
	404949-88-8P	404949-90-2P	404949-92-4P	404949-94-6P	404949-95-7P
	404949-97-9P	404949-99-1P	404950-01-2P	404950-03-4P	404950-04-5P
	404950-05-6P	404950-06-7P	404950-07-8P	404950-08-9P	404950-09-0P
	404950-10-3P	404950-11-4P	404950-12-5P	404950-13-6P	404950-14-7P
	404950-15-8P	404950-16-9P	404950-17-0P	404950-18-1P	404950-19-2P
	404950-20-5P	404950-21-6P	404950-22-7P	404950-23-8P	404950-24-9P
	404950-25-0P	404950-26-1P	404950-27-2P	404950-28-3P	404950-29-4P
	404950-30-7P	404950-31-8P	404950-32-9P	404950-33-0P	404950-34-1P
	404950-35-2P	404950-36-3P	404950-37-4P	404950-38-5P	404950-39-6P
	404950-40-9P	404950-41-0P	404950-42-1P	404950-43-2P	404950-44-3P
	404950-45-4P	404950-46-5P	404950-47-6P	404950-48-7P	404950-49-8P
	404950-50-1P	404950-51-2P	404950-52-3P	404950-53-4P	404950-54-5P
	404950-55-6P	404950-56-7P	404950-57-8P	404950-58-9P	404950-59-0P
	404950-60-3P	404950-61-4P	404950-62-5P	404950-63-6P	404950-64-7P
	404950-65-8P	404950-67-0P	404950-68-1P	404950-69-2P	404950-70-5P
	404950-71-6P	404950-72-7P	404950-73-8P	404950-74-9P	404950-75-0P
	404950-76-1P	404950-77-2P	404950-78-3P	404950-79-4P	
	<u>404950-80-7P</u>	404950-81-8P	404950-82-9P	404950-83-0P	
	404950-85-2P	404950-86-3P	404950-87-4P	404950-88-5P	404950-89-6P
	404950-90-9P	404950-91-0P	404950-92-1P	404950-93-2P	404950-94-3P
	404950-95-4P	404950-96-5P	404950-97-6P	404950-98-7P	404950-99-8P
	404951-01-5P	404951-02-6P	404951-04-8P	404951-05-9P	404951-06-0P
	404951-07-1P	404951-08-2P	404951-09-3P	404951-10-6P	404951-11-7P
	404951-12-8P	404951-13-9P	404951-14-0P	404951-16-2P	404951-17-3P
	(preparation of hydroxamic acids as deacetylase inhibitors)				
IT	404951-18-4P	404951-20-8P	404951-21-9P	404951-22-0P	404951-23-1P
	404951-25-3P	404951-27-5P	404951-29-7P	404951-31-1P	404951-32-2P
	404951-33-3P	404951-34-4P	404951-35-5P	404951-36-6P	404951-37-7P
	404951-38-8P	404951-39-9P	404951-40-2P	404951-41-3P	404951-42-4P
	404951-43-5P	404951-44-6P	404951-45-7P	404951-46-8P	404951-47-9P
	404951-48-0P	404951-49-1P	404951-50-4P	404951-51-5P	
	<u>404951-52-6P</u>	404951-54-8P	404953-24-8P		

(preparation of hydroxamic acids as deacetylase inhibitors)


IT 404950-80-7P 404951-52-6P

(preparation of hydroxamic acids as deacetylase inhibitors)

RN 404950-80-7 USPAT2

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 404951-52-6 USPAT2

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



> d his

(FILE 'HOME' ENTERED AT 06:51:19 ON 28 JAN 2008)

FILE 'CAPLUS' ENTERED AT 06:52:24 ON 28 JAN 2008

E US20060270730 /PN

L1 1 S US20060270730 /PN
SEL RN

FILE 'REGISTRY' ENTERED AT 06:55:00 ON 28 JAN 2008

L2 31 S E13-43

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 06:56:50 ON 28 JAN 2008

L3 951495 S (REJECT? OR GRAFT OR TRANSPLANT? OR ORGAN)

L4 18877 S L3 AND L2

L5 220 S DACINOSTAT OR NVP (W) LAQ (W) 824 OR 404951-53-7/RN OR 40495

L6 104 S L3 AND L5

L7 7 S L6 AND AY<2004

L8 6 S L6 AND AY<2003

L9 1 S L7 NOT 6

L10 0 S L7 NOT L6

L11 7 S L9 OR L8

```

> s wo0222577/pn
L1          0 WO0222577/PN
            (WO222577/PN)

=> s wo200222577/pn
L2          1 WO200222577/PN
            (WO2002022577/PN)

=> sel rn
E1 THROUGH E274 ASSIGNED

=> s 404950-80-7/rn and l2
        67 404950-80-7
        3 404950-80-7D
        67 404950-80-7/RN
            (404950-80-7 (NOTL) 404950-80-7D )
L3          1 404950-80-7/RN AND L2

```

```

=> d ibib hitsr iabs kwic
'HITSR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

```

The following are valid formats:

```

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
        SCAN must be entered on the same line as the DISPLAY,
        e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
        containing hit terms
HITRN ----- HIT RN and its text modification

```

HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes. For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO. You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):
ENTER DISPLAY FORMAT (BIB):end

=> d ibib hitstr iabs kwic

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:220554 CAPLUS <<LOGINID::20080128>>
DOCUMENT NUMBER: 136:262995
TITLE: Preparation of hydroxamic acids as deacetylase
inhibitors
INVENTOR(S): Bair, Kenneth Walter; Green, Michael A.; Perez,
Lawrence B.; Remiszewski, Stacy W.; Sambucetti, Lidia;
Versace, Richard William; Sharma, Sushil Kumar
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis-Erfindungen
Verwaltungsgesellschaft mbH; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022577	A2	20020321	WO 2001-EP10037	20010830 <--
WO 2002022577	A3	20020906		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420899	A1	20020321	CA 2001-2420899	20010830
AU 200182129	A	20020326	AU 2001-82129	20010830
BR 2001013669	A	20030603	BR 2001-13669	20010830
EP 1318980	A2	20030618	EP 2001-960717	20010830

EP 1318980	B1	20071031		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000880	A2	20030828	HU 2003-880	20010830
JP 2004509105	T	20040325	JP 2002-526830	20010830
JP 4012819	B2	20071121		
NZ 524365	A	20041126	NZ 2001-524365	20010830
RU 2302408	C2	20070710	RU 2003-108857	20010830
AT 376999	T	20071115	AT 2001-960717	20010830
EP 1870399	A1	20071226	EP 2007-115019	20010830
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, RO, SI				
US 2003018062	A1	20030123	US 2001-944275	20010831
US 6552065	B2	20030422		
US 2004024067	A1	20040205	US 2002-299518	20021119
IN 2003CN00306	A	20050408	IN 2003-CN306	20030220
ZA 2003001423	A	20040421	ZA 2003-1423	20030221
NO 2003000867	A	20030225	NO 2003-867	20030225
MX 2003PA01832	A	20030604	MX 2003-PA1832	20030228
US 2005085507	A1	20050421	US 2004-984501	20041109
US 7067551	B2	20060627		
US 2006189674	A1	20060824	US 2006-408129	20060420
PRIORITY APPLN. INFO.:			US 2000-229943P	P 20000901
			US 2001-292232P	P 20010518
			US 2001-307490P	P 20010724
			EP 2001-960717	A3 20010830
			WO 2001-EP10037	W 20010830
			US 2001-944275	A1 20010831
			US 2002-299518	A1 20021119
			US 2004-984501	A1 20041109

OTHER SOURCE(S): MARPAT 136:262995

IT 404950-80-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxamic acids as deacetylase inhibitors)



RN 404950-80-7 CAPLUS

CN 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



GRAPHIC IMAGE:



ABSTRACT:

The title compds. [I; R1 = H, halo, alkyl; R2 = H, alkyl, cycloalkyl, etc.; R3, R4 = H, alkyl, acyl, acylamino; or R3 and R4 together with the carbon atom to which they are bound = CO, CS, C:NR8; or R2 together with the N atom to which is bound and R3 together with the C atom to which it is bound form heterocycloalkyl, heteroaryl, etc.; R5 = H, alkyl, aryl, etc.; n1-n3 = 0-6; X, Y = H, halo, alkyl, etc.; R8 = H, alkyl, aryl, etc.] which are deacetylase inhibitors and therefore suitable for pharmaceutical compns. having anti-proliferative properties, were prepared E.g., a 3-step synthesis of II, starting with 4-formylcinnamic acid, was given. The exemplified compds. I showed IC50 of 0.005-0.5 μ M against HDA.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022577	A2	20020321	WO 2001-EP10037	20010830 <--
	WO 2002022577	A3	20020906		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2420899	A1	20020321	CA 2001-2420899	20010830
	AU 200182129	A	20020326	AU 2001-82129	20010830
	BR 2001013669	A	20030603	BR 2001-13669	20010830
	EP 1318980	A2	20030618	EP 2001-960717	20010830
	EP 1318980	B1	20071031		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2003000880	A2	20030828	HU 2003-880	20010830
	JP 2004509105	T	20040325	JP 2002-526830	20010830
	JP 4012819	B2	20071121		
	NZ 524365	A	20041126	NZ 2001-524365	20010830
	RU 2302408	C2	20070710	RU 2003-108857	20010830
	AT 376999	T	20071115	AT 2001-960717	20010830

EP 1870399 A1 20071226 EP 2007-115019 20010830
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE, TR, RO, SI

US 2003018062	A1	20030123	US 2001-944275	20010831
US 6552065	B2	20030422		
US 2004024067	A1	20040205	US 2002-299518	20021119
IN 2003CN00306	A	20050408	IN 2003-CN306	20030220
ZA 2003001423	A	20040421	ZA 2003-1423	20030221
NO 2003000867	A	20030225	NO 2003-867	20030225
MX 2003PA01832	A	20030604	MX 2003-PA1832	20030228
US 2005085507	A1	20050421	US 2004-984501	20041109
US 7067551	B2	20060627		
US 2006189674	A1	20060824	US 2006-408129	20060420

IT	404948-38-5P	404948-39-6P	404948-40-9P	404948-41-0P	404948-42-1P
	404948-43-2P	404948-44-3P	404948-45-4P	404948-46-5P	404948-47-6P
	404948-48-7P	404948-49-8P	404948-50-1P	404948-51-2P	404948-52-3P
	404948-54-5P	404948-55-6P	404948-56-7P	404948-57-8P	404948-58-9P
	404948-59-0P	404948-61-4P	404948-62-5P	404948-63-6P	404948-64-7P
	404948-65-8P	404948-66-9P	404948-67-0P	404948-68-1P	404948-69-2P
	404948-70-5P	404948-71-6P	404948-72-7P	404948-73-8P	404948-74-9P
	404948-75-0P	404948-76-1P	404948-77-2P	404948-78-3P	404948-79-4P
	404948-80-7P	404948-81-8P	404948-82-9P	404948-84-1P	404948-86-3P
	404948-88-5P	404948-90-9P	404948-92-1P	404948-94-3P	404948-96-5P
	404948-98-7P	404949-00-4P	404949-02-6P	404949-04-8P	404949-06-0P
	404949-08-2P	404949-10-6P	404949-11-7P	404949-12-8P	404949-13-9P
	404949-14-0P	404949-15-1P	404949-16-2P	404949-17-3P	404949-18-4P
	404949-19-5P	404949-20-8P	404949-21-9P	404949-22-0P	404949-23-1P
	404949-24-2P	404949-25-3P	404949-26-4P	404949-27-5P	404949-28-6P
	404949-29-7P	404949-30-0P	404949-32-2P	404949-33-3P	404949-34-4P
	404949-35-5P	404949-36-6P	404949-37-7P	404949-38-8P	404949-39-9P
	404949-40-2P	404949-41-3P	404949-42-4P	404949-43-5P	404949-44-6P
	404949-45-7P	404949-46-8P	404949-47-9P	404949-48-0P	404949-49-1P
	404949-50-4P	404949-51-5P	404949-52-6P	404949-53-7P	404949-54-8P
	404949-55-9P	404949-58-2P	404949-61-7P	404949-64-0P	404949-66-2P
	404949-68-4P	404949-70-8P	404949-72-0P	404949-74-2P	404949-76-4P
	404949-79-7P	404949-81-1P	404949-83-3P	404949-85-5P	404949-86-6P
	404949-88-8P	404949-90-2P	404949-92-4P	404949-94-6P	404949-95-7P
	404949-97-9P	404949-99-1P	404950-01-2P	404950-03-4P	404950-04-5P
	404950-05-6P	404950-06-7P	404950-07-8P	404950-08-9P	404950-09-0P
	404950-10-3P	404950-11-4P	404950-12-5P	404950-13-6P	404950-14-7P
	404950-15-8P	404950-16-9P	404950-17-0P	404950-18-1P	404950-19-2P
	404950-20-5P	404950-21-6P	404950-22-7P	404950-23-8P	404950-24-9P
	404950-25-0P	404950-26-1P	404950-27-2P	404950-28-3P	404950-29-4P
	404950-30-7P	404950-31-8P	404950-32-9P	404950-33-0P	404950-34-1P
	404950-35-2P	404950-36-3P	404950-37-4P	404950-38-5P	404950-39-6P
	404950-40-9P	404950-41-0P	404950-42-1P	404950-43-2P	404950-44-3P
	404950-45-4P	404950-46-5P	404950-47-6P	404950-48-7P	404950-49-8P
	404950-50-1P	404950-51-2P	404950-52-3P	404950-53-4P	404950-54-5P
	404950-55-6P	404950-56-7P	404950-57-8P	404950-58-9P	404950-59-0P
	404950-60-3P	404950-61-4P	404950-62-5P	404950-63-6P	404950-64-7P
	404950-65-8P	404950-67-0P	404950-68-1P	404950-69-2P	404950-70-5P
	404950-71-6P	404950-72-7P	404950-73-8P	404950-74-9P	404950-75-0P
	404950-76-1P	404950-77-2P	404950-78-3P	404950-79-4P	
	<u>404950-80-7P</u>	404950-81-8P	404950-82-9P	404950-83-0P	
	404950-85-2P	404950-86-3P	404950-87-4P	404950-88-5P	404950-89-6P
	404950-90-9P	404950-91-0P	404950-92-1P	404950-93-2P	404950-94-3P
	404950-95-4P	404950-96-5P	404950-97-6P	404950-98-7P	404950-99-8P
	404951-01-5P	404951-02-6P	404951-04-8P	404951-05-9P	404951-06-0P
	404951-07-1P	404951-08-2P	404951-09-3P	404951-10-6P	404951-11-7P
	404951-12-8P	404951-13-9P	404951-14-0P	404951-16-2P	404951-17-3P

404951-18-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of hydroxamic acids as deacetylase inhibitors)